Recent News
On January 8, 2026 the company lowered its fourth-quarter adjusted EBITDA outlook, citing extended maintenance at Freeport, Texas and weaker chlorine demand; credit agencies placed or revised outlooks to negative while select analysts trimmed targets.
Technical Analysis
Directional indicators show an emerging trend in strength (ADX 22.87) but directional momentum points downward: DI+ registered a peak-and-reversal while DI- showed a dip-and-reversal, creating a directional bias that favors downside pressure relative to current valuation and keeping upward moves constrained against the WMDST valuation near $22.02.
Momentum readings confirm bearish pressure: MACD printed a peak-and-reversal and sits below its signal line (MACD 0.30 vs signal 0.52), indicating declining momentum that weighs on the likelihood of a sustained advance toward the mean valuation in the immediate term.
MRO stands positive at 13.17 with a peak-and-reversal, indicating price sits above the model target and therefore carries mean-reverting downside risk; that upside/downside balance reduces confidence in continued appreciation toward the WMDST price target without a shift in momentum.
RSI at 50.5 with a peak-and-reversal reflects neutral-to-slightly-oversold internals rolling over, aligning with the MACD and DI signal set and suggesting any rally will face resistance absent a momentum pickup.
Price sits under short- and long-term averages: close $20.81 below the 20-day average $23.20 and below the 200-day average $21.42, and the 12-day EMA shows a peak-and-reversal. Being below both moving averages and the Ichimoku baseline (Kijun-sen $22.26; Senkou B $22.13) places immediate upside tests near those levels and the SuperTrend upper band at $23.92 as the nearest structural resistance to the WMDST valuation.
Bollinger positioning places the close beneath the lower band readings (lower 1× std-dev $22.18), indicating an extension relative to recent volatility that increases probability of mean reversion toward the middle band rather than breakout continuation. Elevated intraday activity — volume $9,095,562 vs 10-day avg $3,888,808 and 200-day avg $2,459,008 — shows heavy participation on recent moves, which can accelerate mean reversion or deepen momentum depending on follow-through.
Volatility metrics remain elevated (42-day beta 2.06; 52-week beta 1.92), signaling larger amplitude swings that amplify both downside risk and the potential for short-lived recoveries toward the WMDST-valued level.
Fundamental Analysis
Reported fourth-quarter results showed a net loss of ($85.7) million, or ($0.75) per diluted share; quarterly adjusted EBITDA totaled $67.7 million and fourth-quarter sales approximated $1,665.1 million. The quarter reflected operational disruptions, maintenance turnarounds and weaker chlorine demand; management expects structural cost savings from ongoing initiatives and recorded a restructuring charge tied to a planned epoxy plant closure in Brazil.
Company-level earnings metrics align with the reported loss: EPS actual stood at ($0.75) vs an estimate of ($0.69), producing an EPS surprise of -8.70%. Trailing P/E registers negative at -29.34 due to the loss, while forward EPS equals $0.32007 and forward P/E calculates to roughly 66.10, reflecting a valuation that prices recovery into future earnings while current results remain weak.
Revenue growth reads 0.0% year-over-year with quarter-over-quarter movement shown as -100.0% in the supplied point-in-time series; earnings growth shows a quarterly decline of -115.8% but a year-over-year improvement of 32.87%, signaling volatile near-term operating performance amid some annual improvement in profitability metrics.
Cash conversion cycle sits at 0 days with a one-day QoQ improvement, indicating tight working-capital turns despite operational noise. Invested capital totals $3,163,900,000 and cost of debt measures 1.122%, highlighting manageable coupon expense even as net leverage metrics remained elevated at year end per reported liquidity and debt commentary.
WMDST values the stock at a mean target of $22.02. The forward multiple and forward EPS imply a recovery priced into expectations, while negative trailing P/E and the quarterly EBITDA shortfall suggest execution and demand must improve to justify that forward multiple.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-12-31 |
| REPORT DATE: | 2026-01-29 |
| NEXT REPORT DATE: | 2026-04-30 |
| CASH FLOW | Begin Period Cash Flow | — |
| Operating Cash Flow | — | |
| Capital Expenditures | — | |
| Change In Working Capital | — | |
| Dividends Paid | — | |
| Cash Flow Delta | — | |
| End Period Cash Flow | — | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | — | |
| Depreciation and Amortization | — | |
| Research and Development | — | |
| Total Operating Expenses | — | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | — | |
| EBIT | — | |
| Operating Income | — | |
| Interest Income | — | |
| Interest Expense | — | |
| Net Interest Income | — | |
| Income Before Tax | — | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | — | |
| Net Income From Continuing Operations | — | |
| EARNINGS | ||
| EPS Estimate | $ -0.69 | |
| EPS Actual | $ -0.75 | |
| EPS Difference | $ -0.06 | |
| EPS Surprise | -8.696 % | |
| Forward EPS | $ 0.32 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | — | |
| Intangible Assets | — | |
| Net Tangible Assets | — | |
| Total Current Assets | — | |
| Cash and Short-Term Investments | — | |
| Cash | — | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | — | |
| LIABILITIES | ||
| Accounts Payable | — | |
| Short-Term Debt | — | |
| Total Current Liabilities | — | |
| Net Debt | — | |
| Total Debt | — | |
| Total Liabilities | — | |
| EQUITY | ||
| Total Equity | — | |
| Retained Earnings | — | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | — | |
| Shares Outstanding | — | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | — |
| Enterprise Value | — | |
| Enterprise Multiple | — | |
| Enterprise Multiple QoQ | — | |
| Enterprise Multiple YoY | — | |
| Enterprise Multiple IPRWA | — | |
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | — | |
| Asset To Liability | — | |
| Debt To Capital | — | |
| Debt To Assets | — | |
| Debt To Assets QoQ | — | |
| Debt To Assets YoY | — | |
| Debt To Assets IPRWA | — | |
| Debt To Equity | — | |
| Debt To Equity QoQ | — | |
| Debt To Equity YoY | — | |
| Debt To Equity IPRWA | — | |
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | — | |
| Price To Book QoQ | — | |
| Price To Book YoY | — | |
| Price To Book IPRWA | — | |
| Price To Earnings (P/E) | -29.341 | |
| Price To Earnings QoQ | -148.943 % | |
| Price To Earnings YoY | -114.395 % | |
| Price To Earnings IPRWA | — | |
| PE/G Ratio | 0.1 | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | 66.101 | |
| Forward PE/G | -0.226 | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | 0.0 | |
| Cash Conversion Cycle Days QoQ | -100.0 % | |
| Cash Conversion Cycle Days YoY | -100.0 % | |
| Cash Conversion Cycle Days IPRWA | — | |
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | — | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | — | |
| Net Invested Capital | — | |
| Invested Capital | $ 3.2 B | |
| Net Tangible Assets | — | |
| Net Working Capital | — | |
| LIQUIDITY | ||
| Cash Ratio | — | |
| Current Ratio | — | |
| Current Ratio QoQ | — | |
| Current Ratio YoY | — | |
| Current Ratio IPRWA | — | |
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | — | |
| Cost Of Debt | 1.122 % | |
| Interest Coverage Ratio | — | |
| Interest Coverage Ratio QoQ | — | |
| Interest Coverage Ratio YoY | — | |
| Interest Coverage Ratio IPRWA | — | |
| Operating Cash Flow Ratio | — | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | — | |
| Revenue Growth | 0.0 % | |
| Revenue Growth QoQ | -100.0 % | |
| Revenue Growth YoY | -100.0 % | |
| Revenue Growth IPRWA | — | |
| Earnings Growth | -292.308 % | |
| Earnings Growth QoQ | -115.8 % | |
| Earnings Growth YoY | 32.867 % | |
| Earnings Growth IPRWA | — | |
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | — | |
| Free Cash Flow Yield | — | |
| Free Cash Flow Yield QoQ | — | |
| Free Cash Flow Yield YoY | — | |
| Free Cash Flow Yield IPRWA | — | |
| Free Cash Growth | — | |
| Free Cash Growth QoQ | — | |
| Free Cash Growth YoY | — | |
| Free Cash Growth IPRWA | — | |
| Free Cash To Net Income | — | |
| Cash Flow Margin | — | |
| Cash Flow To Earnings | — | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | — | |
| Return On Assets QoQ | — | |
| Return On Assets YoY | — | |
| Return On Assets IPRWA | — | |
| Return On Capital Employed (ROCE) | — | |
| Return On Equity (ROE) | — | |
| Return On Equity QoQ | — | |
| Return On Equity YoY | — | |
| Return On Equity IPRWA | — | |
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |